The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study

C J Tyrrell, G M Blake, P Iversen, A V Kaisary, I Melezinek

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

The impact of bicalutamide (Casodex) monotherapy on bone mineral density (BMD) was investigated in patients with locally advanced prostate cancer. BMD was assessed after treatment with bicalutamide 150 mg daily (n = 21) or by medical castration (goserelin acetate 3.6 mg every 28 days) (n = 8) for a median of 287 weeks. In 38% of castration compared with 17% of bicalutamide patients, femoral neck Z-scores were less than or equal to -1 SD of the reference value (accepted as a two to three times increased risk of fracture) and T-scores were less than or equal to -2.5 SD (World Health Organization definition of osteoporosis in white females). Total hip Z-scores were less than or equal to -1 in 43% of castration patients and 13% of bicalutamide patients. In 38% of patients, lumbar spine BMD was affected by degenerative disease. These preliminary data suggest that there may be an advantage in terms of BMD in using bicalutamide monotherapy compared with castration; a benefit confirmed in a recent prospective randomised study.
Original languageEnglish
Pages (from-to)37 - 42
Number of pages6
JournalWorld Journal of Urology
Volume21
Issue number1
DOIs
Publication statusPublished - May 2003

Fingerprint

Dive into the research topics of 'The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study'. Together they form a unique fingerprint.

Cite this